The receptor TREML4 amplifies TLR7-mediated signaling during antiviral responses and autoimmunity by Ramirez-Ortiz, Zaida G et al.
TREML4 amplifies TLR7-mediated signaling during antiviral 
responses and autoimmunity
Zaida G. Ramirez-Ortiz1,*, Amit Prasad1,*, Jason W. Griffith1, William F. Pendergraft III2, 
Glenn S. Cowley4, David E. Root4, Melissa Tai1, Andrew D. Luster1, Joseph El Khoury1,3, 
Nir Hacohen1,4, and Terry K. Means1
1Center for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and 
Immunology, Massachusetts General Hospital and Harvard Medical School, CNY 149, Room 
8301, 149 13th Street, Charlestown, MA 02129, USA
2University of North Carolina Kidney Center, Burnett Womack Building, Chapel Hill, NC 
27599-7155, USA
3Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
4Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
Abstract
The genes and pathways that fine-tune TLR7-mediated innate inflammatory responses remain to 
be fully elucidated. Using an unbiased genome-scale shRNA screen, we identified the receptor 
TREML4 as an essential positive regulator of TLR7 signaling. Macrophages from Treml4–/– mice 
were hyporesponsive to TLR7 agonists and failed to produce type I interferon due to impaired 
phosphorylation of the transcription factor STAT1 by the MAP kinase p38 and decreased 
recruitment of MyD88 to TLR7. TREML4 deficiency reduced production of inflammatory 
cytokines and autoantibodies in SLE-prone MRL/lpr mice and inhibited the antiviral immune 
response to influenza. Our data identify TREML4 as a positive regulator of TLR7 signaling and 
provide insight into the molecular mechanisms that control antiviral immunity and the 
development of autoimmunity.
In humans and mice combined the Toll-like receptor (TLR) family consists of thirteen 
members that can be divided into two subgroups based on their cellular location1. Cell 
surface TLRs (TLR1, TLR2, TLR4, TLR5 and TLR6) recognize various molecules in 
bacteria and fungi. Intracellular TLRs (TLR3, TLR7, TLR9, TLR13) recognize nucleic 
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acids; TLR3 recognizes double-stranded RNA, TLR7 recognizes single-stranded RNA, and 
TLR9 and TLR13 are receptors for double-stranded DNA and ribosomal RNA, 
respectively2. TLRs are an evolutionarily conserved family of type I transmembrane 
receptors that have an extracellular domain compromising leucine rich repeats and a 
cytoplasmic domain that shares significant homology with the mammalian type I IL-1 
receptor3. The TLRs are germ-line encoded receptors that recognize a myriad of conserved 
microbial-associated molecular patterns (MAMPs) found in many different microbes, such 
as bacteria, fungi, viruses, and parasites. TLR recognition of these MAMPs leads to the 
initiation of intracellular signaling pathways that elicit the expression of inflammatory 
genes, such as cytokines essential for host defense. Upon ligand binding, all TLRs trigger a 
common signal transduction pathway that starts with the recruitment of the intracellular 
adaptor protein MyD88 that mediates the phosphorylation of IRAK1 by IRAK44. 
Phosphorylated IRAK1 associates with TRAF6, which mediates the activation of mitogen-
activated protein kinases (MAPK) and subsequent activation of transcription factors that 
promote cytokine gene expression.
TLR activation is central to early host defense, however excessive activation of the TLR 
signaling pathway can contribute to chronic inflammatory diseases5. Thus, TLR signaling 
must be under tight positive and negative regulation to maintain immune tolerance. 
Recently, members of the triggering receptor expressed on myeloid cells (TREM) family 
have been shown to regulate innate immune responses by amplifying or dampening TLR-
induced signals6-9. TREM and TREML receptors are a structurally similar family of 
receptors consisting of a single extracellular variable-type immunoglobulin (Ig)-like domain, 
a transmembrane domain and a short cytoplasmic tail lacking any known signaling motifs, 
which are expressed predominantly on myeloid cells10. TREM1 promotes the inflammatory 
response to bacteria and the TLR4 ligand LPS6. In contrast, TREM2 and TREML1 suppress 
TLR-induced signals and protect against autoimmunity11-13. The inhibitory TLR signals 
mediated by TREM2 depend upon its interaction with DAP12, a transmembrane-anchored 
signaling adaptor containing an ITAM within its cytoplasmic domain8,14. The ligands for 
TREM receptors have largely remained elusive, however several reports suggest that TREM 
receptors can bind to microbial and host molecules. TREML4 has been shown to bind late 
apoptotic and necrotic cells15 and TREML1 to fibrinogen11, whereas TREM1 and TREM2 
recognize anionic ligands from bacteria16.
TLRs have also been implicated in the development and exacerbation of chronic 
inflammatory syndromes and autoimmunity through their inappropriate activation by 
endogenous self ligands, such as nucleic acids released from necrotic cells, including in the 
development and progression of the autoimmune disease systemic lupus erythematosus 
(SLE)2,5,17. Dysregulated activation of TLR7 has been implicated in the pathogenesis of 
SLE in humans and mice. Male BXSB mice with a Y-linked autoimmune accelerator locus 
(Yaa) develop spontaneous SLE-like disease due to a duplication of a 4-Mb gene segment 
containing TLR7 transposed to the Y chromosome18,19. This duplication is responsible for 
the autoimmune phenotype in Yaa male mice, because reduction of TLR7 copy number 
abrogated disease20. Furthermore, MRL/lpr mice that spontaneously develop SLE have 
significantly reduced renal disease and autoantibodies to RNA-associated autoantigens when 
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backcrossed to TLR7-deficient mice21,22. Finally, TLR7 single nucleotide polymorphisms 
(SNPs) have been identified that are associated with increased transcript expression and 
increased risk for SLE in humans23. Together, these observations indicate that TLR7 
signaling is critical for SLE-specific autoimmunity.
To identify genes required for TLR7-mediated immune cell activation, we performed a 
genome-scale RNA-mediated interference (RNAi)-based screen in murine macrophages and 
identified TREML4 is a positive regulator of TLR signaling. TREML4 was required for 
TLR7-mediated responsiveness to TLR7 ligands and promoted TLR7-induced activation 
and phosphorylation of p38 MAPK and STAT1 and the trafficking and localization of 
MyD88 and TLR7 to endosomes. We also show that TREML4 is critical for the antiviral 
immune response to the ssRNA influenza virus. Finally, TREML4 deficiency ameliorated 
inflammatory cytokine production and kidney disease in SLE-prone MRL/lpr mice. Thus, 
our findings demonstrate a critical role for TREML4 in promoting TLR7-mediated cytokine 
production during antiviral responses and the development of autoimmunity.
Results
TREML4 positively regulates the TLR7 pathway
To identify genes and pathways required for TLR7-induced cell activation, we performed an 
unbiased genome-scale pooled lentivirus-based RNAi screen with a 40k shRNA library 
developed by The RNAi Consortium24,25. Mouse RAW 264.7 macrophages stably 
transfected with an NF-κB-responsive endothelial leukocyte adhesion molecule-1 (ELAM 
-1) promoter driving expression of enhanced green fluorescent protein (RAW-GFP) were 
transduced with a pool of ∼40,000 lentivirally encoded short hairpin RNAs (shRNAs). With 
this approach ∼8,000 murine genes were targeted by 5 or more independent shRNAs per 
gene and cells received an average of ∼0.3 shRNAs [multiplicity of infection (MOI = 0.3]. 
Each shRNA was introduced to ∼200 independent cells. shRNA-transduced cells were 
treated with the synthetic TLR7 specific agonist gardiquimod (GRD) for 6 hours and sorted 
by flow cytometry into two populations based on the expression of TNF and NF-κB-GFP: 
TNFloGFPlo and TNFhiGFPhi. The shRNA sequences were then amplified by PCR from the 
genomic DNA isolated from the two cell populations and hybridized to complementary 
microarrays. To identify the shRNAs that inhibited GRD-induced TNF and NF-κB 
expression (i.e. positive regulators of TLR7 signaling), we measured the overrepresentation 
of shRNAs that were repeatedly present in the TNFloGFPlo sorted population of RAW-GFP 
cells compared to the TNFhiGFPhi subset. Using this approach, we identified 257 enriched 
shRNAs with a log fold-difference greater than 2 and a P-value less than 0.05 (Fig. 1a and 
Supplementary Table 1). In the TNFloGFPlo subset we identified an enrichment of shRNAs 
that targeted genes with well-established roles in the TLR7 signaling pathway, such as 
TLR7, MyD88, IRAK2, IRAK4, TRAF6 and IRF7. In addition, we identified several genes 
that have not been previously described as positive regulators of TLR7 signaling. Among 
these, an shRNA targeting TREML4 was the 11th most enriched shRNA in our RNAi-based 
screen out of the ∼40,000 shRNAs tested (LFC=3.42; P=0.012; Fig. 1a and Supplementary 
Table 1). To validate the screen results, we independently transfected RAW-GFP reporter 
cells with two different shRNAs that targeted two distinct regions of TREML4 and 
Ramirez-Ortiz et al. Page 3













possessed different sequences in the seed region that is known to mediate off-target effects. 
Quantitative PCR (qPCR) and immunoblotting in the RAW-GFP transfected cells showed 
that both hairpins effectively knocked down TREML4 (Fig. 1b,c), and found a significant 
correlation between the reduced expression of TREML4 mRNA and protein and diminished 
TNF and NF-κB-GFP expression in response to TLR7 stimulation (Fig. 1d). These data are 
the first demonstration that TREML4 is a positive regulator of TLR7 signaling. To 
determine whether TREML4 regulates the signaling pathways downstream of other TLRs, 
we transfected RAW-GFP cells with shRNA-encoding viruses to silence MyD88 or 
TREML4 expression and treated them with agonists for TLR2-TLR1 (Pam3CSK4), TLR2-
TLR6 (zymosan), TLR3 (pIC), TLR4 (lipopolysaccharide, LPS), TLR9 (CpG-DNA) or 
TLR13 (rRNA). Silencing of Treml4 expression significantly reduced the ability of RAW-
GFP cells to induce NF-κB-GFP and TNF expression in response to TLR7, TLR9 and 
TLR13 agonists, but not to other TLR ligands (Fig. 1e). These data demonstrate that 
TREML4 is a positive regulator for a limited sub-group of intracellular TLRs in RAW 
macrophages.
We next tested whether TREML4 overexpression could amplify TLR signaling. Human 
embryonic kidney (HEK) cells stably expressing TREML4 were transfected with plasmids 
containing TLR2, TLR3, TLR4, TLR7, TLR9 or TLR13 cDNA and stimulated with their 
cognate agonists. TREML4 overexpression significantly amplified TLR7-, TLR9- and 
TLR13-mediated induction of Il8 mRNA in HEK cells transfected with TLR7, TLR9, or 
TLR13, respectively (Fig. 1f and Supplementary Fig. 1a). HEK cells overexpressing 
TREML4 in the absence of TLR7 overexpression did not produce Il8 mRNA in response to 
TLR7 agonists (Fig. 1f) indicating that TREML4 is not activated directly by TLR7 ligands.
To test if TREML4 regulates TLR7 signaling through its association with intracellular 
adaptors, we transfected TLR7-expressing HEK cells with plasmids encoding wild-type 
TREML4(WT), TREML4 lacking the cytoplasmic domain TREML4(Δcyto) or a TREML4 
containing a point mutation in the transmembrane domain TREML4(K210L) and measured 
Il8 mRNA levels following stimulation with the TLR7 ligand GRD. We found that the 
cytosolic domain of TREML4 was only modestly required for TLR7 signaling (Fig. 1g). In 
contrast, HEK cells expressing TREML4(K210L) had a significant impairment in TLR7-
induced Il8 mRNA compared to TREML4(WT) expressing HEK cells, indicating that the 
charged lysine residue in the TM domain is required for TREML4-mediated amplification of 
TLR7 signaling (Fig. 1g).
Human and mouse TREML4 share about 40% amino acid identity, however human 
TREML4 is truncated compared to its mouse counterpart due to insertion of a stop codon 
just downstream of the charged lysine residue in the TM domain. To determine whether 
human TREML4 regulates TLR7 signaling, we silenced TREML4 expression in the human 
THP-1 monocyte cell line by lentiviral transduction of Treml4-specific shRNAs. Treml4-
silenced THP-1 cells had a reduced expression of Il8 mRNA following stimulation with the 
TLR7 ligand GRD compared to THP-1 cells transduced with control shRNAs (Fig. 1h), 
indicating an evolutionarily conserved function for TREML4 in the regulation of TLR7 
signaling.
Ramirez-Ortiz et al. Page 4













Because TREML4 binds to late apoptotic and necrotic cells15 and because nucleic acids can 
accumulate in apoptotic blebs or leak from necrotic cells, we tested whether nucleic acid 
ligands for TLR7, TLR9 and TLR13 could bind and trigger TREML4 signaling. Because 
little is known about the signaling pathways and targets downstream of TREM receptors, we 
constructed a chimeric protein containing the extracellular domain of TREML4 fused to the 
intracellular domain of the tumor-necrosis factor (TNF) receptor TNF-R1 and overexpressed 
it in HEK cells. The TREML4-TNF-R1 chimeric receptor allowed the quantitation of ligand 
binding to TREML4 through induction of the TNF-R1-dependent signaling pathway that 
leads to the activation of the transcription factor NF-κB and expression of Il8 mRNA in 
HEK cells26. Treatment with late apoptotic cells induced robust induction of Il8 mRNA in 
cells expressing TREML4-TNF-R1 but not those expressing DECTIN1-TNF-R1 
(Supplementary Fig. 1b), which indicated a direct interaction between TREML4 and 
apoptotic cells. In contrast, we observed only weak induction of Il8 mRNA (<2 fold) 
following stimulation with GRD, CpG-DNA or rRNA compared to mock transfected cells 
(Supplementary Fig. 1b), suggesting that nucleic acids are not cognate ligands for TREML4. 
Together these results identified mouse and human TREML4 as a positive regulator of 
TLR7, TLR9 and TLR13 signaling.
TREML4 positively regulates TLR7, TLR9, and TLR13 signaling
We performed qPCR analysis to examine the expression of Treml4 mRNA in various organs 
in wild-type B6 mice. Treml4 was mainly expressed in the spleen (Supplementary Fig. 2a). 
Treml4 expression was low or absent on endothelial cells (EC), B cells, T cells and NK 
cells, but detectable on macrophages, DCs, neutrophils, bone marrow-derived DC (BMDC) 
and bone marrow-derived macrophages (BMDM; Supplementary Fig. 2b), consistent with 
published reports suggesting restricted TREML4 expression on splenic macrophages and 
DCs 15,27. In addition, in vitro stimulation with the TLR7 ligand GRD induced a rapid 
increase of Treml4 mRNA expression in cultured splenic macrophages (Fig. 2a).
To further examine the role of TREML4 in regulating TLR7 responses, we generated 
TREML4-deficient (Treml4–/–) mice in which TREML4 expression was ablated by 
replacement of exons 2-4, which encode most of the extracellular domain, with a neomycin 
resistance cassette (Fig. 2b,c and Supplementary Fig. 2c). To determine whether TREML4 
was required for TLR7-induced gene expression in splenic macrophages, we measured the 
induction of mRNA for various cytokines, chemokines and transcription factors in GRD-
stimulated splenic macrophages from wild-type littermates and Treml4–/– mice. Compared 
to wild-type cells, Treml4–/– splenic macrophages mice had a significant impairment in the 
induction of 21 genes known to be activated by the TLR7 pathway (Fig. 2d), such as pro-
inflammatory cytokine and chemokine expression, type I IFN and IFN-induced genes, such 
as Cxcl10, Cxcl9 and Stat1. We also stimulated wild-type and Treml4–/– splenic 
macrophages with agonists for TLR2, TLR3, TLR4, TLR7, TLR9 or TLR13. Treml4–/– 
splenic macrophages mice had a significant impairment in GRD, CpG-DNA and rRNA-
induced Tnf mRNA expression compared to wild-type macrophages (Fig. 2e), confirming 
the results obtained using shRNA knockdown of TREML4 in the RAW cells (Fig. 1e). 
ELISA performed on the supernatants of GRD-, CpG-DNA- or LPS-stimulated splenic 
macrophages showed that secretion of TNF, IL-12p40, IFN-β and the IFN-inducible 
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chemokine CXCL10 protein was significantly impaired in Treml4–/– macrophages compared 
to wild-type macrophages in response to GRD stimulation (Fig. 2f), while secretion of IFN-
β and CXCL10 was similar, and TNF and IL-12p40 production was significantly impaired in 
Treml4–/– compared to wild-type macrophages in response to CpG-DNA stimulation (Fig. 
2f). These results suggest that TLR7-mediated activation of the IFN pathway is TREML4-
dependent, while TLR9-mediated activation of the IFN pathway is TREML4-independent. 
We found no differences in cytokine production between wild-type and Treml4–/– 
macrophages in response to LPS stimulation (Fig. 2f), indicating that TREML4 is not 
involved in regulating the TLR4 pathway.
We also examined whether TREML4 modified TLR-induced cytokine production in 
neutrophils. We found that CD11b+Ly6g+ cells (neutrophils) isolated by magnetic bead-
based negative selection from the bone marrow of Treml4–/– mice had a significant 
impairment in GRD- and rRNA-induced Cxcl2 mRNA expression compared to wild-type 
neutrophils, suggesting that TLR7 and TLR13-mediated induction of Cxcl2 in neutrophils is 
TREML4-dependent (Supplementary Fig. 2d). In contrast, Treml4–/– neutrophils migrated 
normally in response to the peptide chemoattractant formyl-Methionyl-Leucyl-
Phenylalanine (fMLP) in a transwell chemotaxis assay and had normal ability to 
phagocytose opsonized latex beads compared to wild-type neutrophils (Supplementary Fig. 
2e,f), suggesting that migration and phagocytic pathways in neutrophils are TREML4-
independent. Collectively, these data indicate that TREML4 is a nonredundant positive 
regulator of TLR7, TLR9 and TLR13 signaling in splenic macrophages and neutrophils.
TREML4 is critical for responses to ssRNA and influenza virus
To test whether TREML4 also regulated TLR7 responses to other synthetic and natural 
ligands, such as the synthetic imidazoquinoline compound R-848 and the ssRNA influenza 
virus28, we injected GRD, R-848, CpG-DNA or LPS intravenously (i.v.) or live influenza 
AZ/PR8/34 (PR8) virus intranasally (i.n.) into wild-type and Treml4–/– mice and assessed 
the induction of TNF, IL-12p40, IFN-β and CXCL10 mRNA and protein by qPCR analysis, 
flow cytometry and ELISA at 8 h post-injection in the spleens and blood serum. Splenocytes 
from wild-type mice injected with GRD, R-848 or influenza had high expression of Tnf, 
Il12b, Ifnb and Cxcl10 mRNA (Fig. 3a). In contrast, splenocytes isolated from Treml4–/– 
mice injected with GRD, R-848 or influenza virus showed a marked impairment in the 
production of these inflammatory cytokines (Fig. 3a). Intracellular flow cytometry showed 
that F4/80hiCD11bloCD11c– splenic macrophages from GRD, R-848, influenza or CpG-
DNA injected Treml4–/– mice produced significantly lower amounts of TNF protein 
compared to wild-type macrophages (Fig. 3b). The amounts of TNF and IL-12p40 protein in 
the serum were significantly reduced in Treml4–/– mice compared to wild-type mice 
following injection with GRD, R-848, CpG-DNA, LPS or influenza virus (Fig. 3c). Serum 
IFN-β and CXCL10 were significantly reduced in GRD, R-848 or influenza virus injected 
Treml4–/– mice as compared to wild-type mice, but were induced at similar levels as in wild-
type controls by CpG-DNA or LPS (Fig. 3c), indicating that the TLR7-mediated activation 
of the IFN pathway in vivo is TREML4-dependent, while the TLR9- and TLR4-mediated 
activation of the IFN pathway in vivo is TREML4-independent.
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To further examine the role of TREML4 in the antiviral host defense to influenza, we 
monitored weight loss and viral load in wild-type and Treml4–/– mice infected i.n. with a 
sublethal dose of influenza. Treml4–/– mice lost weight with similar kinetics compared to 
wild-type littermate control mice during the first week of infection (Fig. 3d). However, 
Treml4–/– mice continued to lose weight by day 9 post-infection, while wild-type control 
mice plateaued and then began to gain weight steadily (Fig. 3d). Wild-type mice cleared the 
influenza virus between 10-14 days after primary infection and most mice survived (Fig. 
3e,f), while viral burden in the lungs of Treml4–/– mice was significantly higher than in 
wild-type at day 10 and a majority of the mice succumbed to infection (Fig. 3e,f). Together 
these data demonstrate that TREML4 is necessary to control the early antiviral response to 
i.n. influenza virus infection and to restrict the viral load in the lung of infected mice.
To determine whether TREML4 was required for the immune response to other pathogenic 
viruses, we measured the expression of Tnf mRNA by qPCR in splenic macrophages 
isolated from wild-type and Treml4–/– mice cultured with vesicular stomatitis virus (VSV), a 
ssRNA virus, or cytomegalovirus (CMV), a dsDNA virus. Treml4–/– macrophages had a 
significant impairment in VSV- and CMV-induced Tnf mRNA expression compared to 
wild-type macrophages (Supplementary Fig. 3a), suggesting that TREML4 may play an 
important role in the antiviral immune response to a wide range of human pathogenic 
viruses.
To test whether TREML4 deficiency in Treml4–/– mice had affected the cellular expression 
of TLR7 and/or members of the TLR7 signaling pathway, we examined the expression of 
TLR7 in splenic macrophages and DCs from Treml4–/– mice. As assessed by intracellular 
flow cytometry, TLR7 expression in Treml4–/– cells was similar to that found in wild-type 
cells (Supplementary Fig. 3b). In addition, we found that untreated splenic macrophages 
from wild-type and Treml4–/– mice expressed similar amounts of genes critical for TLR7 
signaling, such as Tlr7, Myd88, Irak1, Irak3, Irak4, Traf6, Tbk1, Syk, Dap12, Irf5, Irf7, 
Stat1, and Stat2 (Supplementary Fig. 3c), suggesting decreased expression of TLR7 or other 
proteins in the TLR7 pathway does not account for the hyporesponsiveness to GRD, R-848 
or influenza virus challenge observed in Treml4–/– mice. Collectively, these data 
demonstrate the essential role of TREML4 in the antiviral host response to influenza 
infection.
TREML4 regulates TLR7-induced phosphorylation of MAPK and STAT1
We next assessed the molecular mechanism of Treml4–/– macrophage hyporesponsiveness to 
TLR7 agonists. To determine whether TREML4 regulates TLR ligand-induced MAPK 
activation, we stimulated BMDC prepared from wild-type and Treml4–/– mice with LPS, 
GRD or CpG-DNA and determined phospho-p44p42 and phospho-p38 accumulation using 
intracellular flow cytometry. GRD stimulation caused a rapid (within 15 min) increase in 
phospho-p44p42 and phospho-p38 in wild-type BMDC but not in TREML4-deficient 
BMDC (Fig. 4a,b). Following CpG-DNA stimulation, phosphorylation of p44p42, but not 
p38, was reduced in Treml4–/– BMDC compared to wild-type cells (Fig. 4a,b), suggesting 
that TREML4 differentially regulates TLR7 and TLR9 signaling pathways. We observed no 
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differences in the ability of LPS to activate MAPKs in wild-type and Treml4–/– BMDC (Fig. 
4a,b).
Activation of the transcription factor STAT1 is required for the production of IFN and IFN-
regulated genes. Full activation of STAT1 occurs by phosphorylation of its Ser727 and 
Tyr701 residues29. Ser727 phosphorylation is mediated by TLR-induced p38 MAPK, while 
Y701 phosphorylation is dependent on autocrine type I IFN signaling30. Thus, Ser727 
phosphorylation of STAT1 is TLR-dependent and IFN-independent, while tyrosine701 
phosphorylation is TLR-independent and IFN-dependent. To test whether TREML4 
regulated the TLR7-induced Ser727 phosphorylation of STAT1, we stimulated wild-type 
and Treml4–/– BMDC with LPS, GRD or CpG-DNA and determined induction of STAT1 
Ser727 phosphorylation by intracellular flow cytometry. STAT1 Ser727 phosphorylation 
was observed in LPS, GRD and CpG-DNA-stimulated wild-type BMDC and LPS or CpG-
DNA-stimulated Treml4–/– BMDC, but not in GRD-stimulated Treml4–/– BMDC (Fig. 4c). 
These data indicated that the TLR7-mediated activation of p38 and STAT1 Ser727 
phosphorylation were TREML4-dependent, while the TLR4- and TLR9-mediated activation 
of p38 and STAT1 were TREML4-independent. In addition, we found that STAT1 Tyr701 
phosphorylation was significantly impaired in Treml4–/– BMDCs treated with GRD 
compared to wild-type BMDCs (Fig. 4d), suggesting that TREML4 also amplifies IFNAR1 
signaling. Because IFN-α, IFN-β, and CXCL10 expression is induced by STAT1, these 
observations are consistent with the reduced induction of these genes in response to TLR7, 
but not TLR4 or TLR9 stimulation, and suggests that TREML4 may mediate the cross-talk 
between the TLR, IFN and STAT1 signaling pathways31.
TREML4 regulates MyD88 and TLR7 trafficking and localization
To determine whether TREML4 regulates the intracellular trafficking of MyD88 to TLR7, 
we examined if TLR7 and MyD88 interact following GRD stimulation. TLR7 and MyD88 
co-immunoprecipitated in GRD-stimulated wild-type BMDCs, while this association was 
not observed in Treml4–/– BMDCs. Binding and recruitment of MyD88 to TLR7 was 
TREML4-dependent (Fig. 5a). We also investigated the recruitment of MyD88 to TLR7 by 
confocal microscopy in BMDCs stimulated with GRD for 5 or 15 minutes, and stained with 
fluorescently-labeled antibodies against TLR7 and Myd88. We observed a significant 
impairment in the trafficking and co-localization of MyD88 and TLR7 in Treml4–/– BMDC 
compared to wild-type BMDC (Fig. 5b), suggesting that TREML4 regulates TLR7 signaling 
by controlling the recruitment of MyD88 to TLR7. To investigate whether TREML4 
regulates the trafficking of TLR7 from the ER to endosomal and lysosmal compartments 
after stimulation, we stimulated wild-type and Treml4–/– BMDCs with GRD for 5 or 15 
minutes, followed by staining with fluorescently-labeled antibodies against TLR7, the 
endosome marker EEA1 or the lysosomal-associated membrane protein LAMP1. Confocal 
microscopy showed a significant impairment in the trafficking and co-localization of TLR7 
to EEA1 or LAMP1 in Treml4–/– BMDC compared to wild-type BMDC (Fig. 5c). Together, 
these results demonstrate that TREML4 regulates TLR7 signaling by controlling the 
recruitment of TLR7 to endosomes and lysosomes where it interacts with MyD88 to initiate 
signaling.
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TREML4-deficiency reduces autoimmunity in mice
To assess the impact of TREML4 deficiency on autoimmunity, we backcrossed Treml4–/– 
mice for eight generations with MRL/lpr mice, which spontaneously develop an 
autoimmune disease with clinical features similar to human SLE, including autoantibody 
generation, immune cell activation and lethal glomerulonephritis. We used a HEp-2 
antinuclear antibody (ANA) indirect fluorescent antibody assay for detecting antibodies to 
both RNA- and DNA-containing autoantigens in the sera of Treml4–/– MRL/lpr and wild-
type MRL/lpr mice. At 16 weeks of age, sera from most MRL/lpr mice (∼96%) produced a 
homogenous (anti-DNA) or speckled (anti-RNA) pattern of nuclear ANA, while only 40% 
of Treml4–/– MRL/lpr serum samples showed proof of nuclear ANA production (Fig. 6a). 
ELISA for autoantibodies to nucleosomes, which detects anti-histones and anti-dsDNA 
autoantibodies, showed significantly lower concentration of autoantibodies in Treml4–/– 
MRL/lpr mice than in MRL/lpr mice (Fig. 6b). ELISA to quantify autoantibodies to the 
dsDNA and RNA-containing Sm-RNP autoantigen showed that the generation of DNA and 
Sm-RNP autoantibodies was significantly reduced in Treml4–/– MRL/lpr mice compare to 
wild-type MRL/lpr mice (Fig. 6c,d). In addition, the highly specific Crithidia luciliae 
immunofluorescence assay showed a substantial decrease in autoantibodies binding to the 
dsDNA of the C. luciliae kinetoplast in sera from Treml4–/– MRL/lpr sera (data not shown). 
These results are consistent with previous reports demonstrating an impairment in the 
generation of autoantibodies to RNA- and DNA-containing autoantigens in MRL/lpr mice 
deficient in TLR7 and TLR9 signaling21.
We observed a significant decrease in the number of CD4+ T cells, CD8+ T cells, and pDCs 
in the spleen and lymph nodes of Treml4–/– MRL/lpr mice compared to wild-type MRL/lpr 
mice (Fig. 6e) as well as in the number of activated CD44+CD4+ T cells in the spleen of 
Treml4–/– MRL/lpr mice (Fig. 6f). Splenocytes from Treml4–/– MRL/lpr mice expressed 
significantly lower mRNA for Cxcl10, Il1a, Il1b, Tnf, Il12b, Ifnb, and Ifna compared to 
wild-type MRL/lpr mice (Fig. 6g) and IFN-α concentration in the serum was significantly 
lower in Treml4–/– MRL/lpr mice compared to MRL/lpr mice (Fig. 6h). Glomerular size, 
cellularity and deposition of protein in periodic acid Schiff-stained kidney sections was 
reduced in Treml4–/– MRL/lpr mice compared to MRL/lpr mice (Fig. 6i). Furthermore, the 
composite renal disease score, which includes several parameters of nephritis such as 
glomerular IgG deposition, urine proteinuria and blood urea nitrogen concentration was 
significantly lower in Treml4–/– MRL/lpr mice compared to their MRL/lpr counterparts 
(Fig. 6j). Consistent with decreased kidney disease, Treml4–/– MRL/lpr mice showed 
significantly better survival (∼88% survival at 26 weeks) than Treml4+/+ MRL/lpr mice 
(∼50% survival at 26 weeks) (Fig. 6k). Finally, both male and female Treml4–/– MRL/lpr 
mice were equally protected against SLE, including autoantibody generation, immune cell 
activation, inflammatory cytokine production and nephritis (data not shown). Collectively 
these data demonstrate an essential role for TREML4 in the regulation of autoimmunity.
Discussion
The data presented here provide new insight into understanding signaling through the 
endosomal TLRs TLR7 and TLR9. We show that TREML4 positively regulates the 
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activation of macrophages, DCs and neutrophils by amplifying TLR7-mediated production 
of inflammatory cytokines, such as type I IFNs during antiviral responses and autoimmune 
diseases. TREML4 amplifies TLR7 signaling by promoting phosphorylation and activation 
of the MAP kinase p38 and of the transcription factor STAT1. Furthermore, TREML4 
expression was essential for the recruitment of MyD88 to TLR7 at endosomes. Together 
these data demonstrated an important role for TREML4 in the regulation of TLR7 signaling 
and that its expression in vivo is required for antiviral host defense to influenza and for 
promotion of TLR7-mediated autoimmune disease.
Our findings demonstrate a unique specificity for TREML4 in promoting DC, macrophage 
and neutrophil activation by ligands for TLR7, TLR9 and TLR13, but not other TLRs. 
TREML4 promoted the induction of STAT1-dependent genes, such as the type I IFN, by 
TLR7-, but not TLR9-stimulated DC. Full activation of STAT1 occurs by phosphorylation 
of the Ser727 residue by the TLR7-induced p38 MAPK and of the Tyr701 residues by 
autocrine IFNAR1 signaling. We found that TREML4 promoted both the TLR7-p38 
MAPK-dependent phosphorylation of Ser727 and the IFNAR1-dependent phosphorylation 
of Tyr701, indicating that in addition to promoting TLR7 signaling, TREML4 also amplifies 
the IFNAR1 pathway, and suggesting that TREML4 may regulate the cross-talk between 
TLR, IFNAR1 and STAT1 signaling pathways31.
The ligands for TREM receptors have largely remained elusive. Our data using a chimeric 
TREML4-TNF-R1 reporter transfected in HEK cells suggests that none of the TLR ligands 
tested bind or activate TREML4 directly. While the TREML4 ligand remains unknown, we 
did demonstrate that amplification of TLR7 signaling by TREML4 was dependent on the 
charged lysine residue present in the transmembrane domain of TREML4. This cationic 
lysine residue is present in the transmembrane domain of several members of the TREM 
family, including TREM1, TREM2, TREM3 and pDC-TREM, and has been shown to be 
required for association to the ITAM-bearing adaptor molecule, DNAX activation protein 12 
kDa (DAP12)32. TREML4 also associates with DAP12, but not DAP10 or Fc receptors15. 
DAP12-deficient macrophages were shown to secrete increased amounts of cytokines after 
TLR stimulation, indicating that DAP12-pairing receptors negatively regulate signaling 
through TLRs14. These data are in agreement with studies showing the DAP12-paired 
receptor TREM2 negatively regulates TLR signaling33. Furthermore, patients with Nasu-
Hakola disease that develop bone cysts and presenile dementia were found to have loss of 
function mutations in either DAP12 or TREM2, indicating that this receptor-signaling 
adaptor pair is crucial for bone remodeling and brain function34,35. In addition, variants in 
TREM2 have been associated with the risk of Alzheimer's disease12,13. Clearly, DAP12 and 
TREM2 negatively regulate inflammatory pathways, however, what remains unclear is how 
DAP12 signaling downstream of TREM1 and TREML4 is involved in the positive 
regulation of TLR signaling pathways. One possibility is that TREM receptors may regulate 
TLR signals in a DAP12-independent manner. Indeed, soluble forms of TREM1 and 
TREM2 are released from cells activated by inflammatory stimulation, and a soluble form of 
TREML4 was shown to bind to dead cells36,37. These soluble TREMs may interact with 
unidentified ligands on cells to amplify or suppress inflammatory pathways. More studies 
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are needed to address whether different signaling pathways are activated via soluble versus 
membrane bound forms of TREM receptors.
While the overexpression and genetic loss of function experiments indicated that TREML4 
is essential in promoting TLR7 signaling, because the ligand for TREML4 is unknown, we 
were unable to induce TREML4 signaling directly and uncover its functions in the absence 
of TLR7 signaling. The development of specific TREML4 agonists will be very useful as a 
tool to decipher the key downstream signaling pathways responsible for TREML4-mediated 
amplification of TLR and IFN signaling, while TREML4 antagonists may have therapeutic 
applications in dampening inflammatory autoimmune diseases. It is also possible that no 
endogenous ligands exist for TREML4, and perhaps similarly to other receptors such as 
TREM2, its expression and signaling through adaptor molecules controls cellular functions 
such as cell surface transport, ectodomain shedding of soluble receptors, phagocytosis and 
co-stimulatory molecule expression38. Similar to mouse TREML4, we found that human 
TREML4 also positively regulates TLR7 signaling. Human TREML4 is highly expressed in 
patients with acute coronary syndrome and coronary artery calcification39,40. These results 
are consistent with the role of TREML4 as an activating receptor and indicate it may have a 
role in cardiovascular disease. Together these data suggest that increased TREML4 
expression could be a useful biomarker for the early detection of chronic disease in patients.
The rescue of the autoimmune phenotype in MRL/lpr mice by TREML4 deletion is similar 
to results obtained in MRL/lpr mice lacking MyD88, TLR7 and TLR9, or injected with dual 
TLR7-TLR9 antagonists, which have significantly lower autoantibody titers to DNA and 
RNA autoantigens and ameliorated disease21,41-44. We propose that in the absence of 
TREML4, MyD88 fails to traffic to TLR7 resulting in disruption of p38 MAPK activation 
and the phosphorylation of the transcription factor STAT1. Similar to STAT1-deficient 
mice, cells lacking TREML4 are unable to produce IFN and IFN-inducible genes, and are 
protected from the development of lupus disease45. Together these data demonstrate 
TREML4 plays a critical role in regulating TLR7 signaling and that therapeutic blocking of 
TREML4 holds considerable promise in preventing autoimmunity.
Although it is appealing to speculate that antagonistic anti-TREML4 therapy could be used 
to prevent and/or dampen lupus disease, caution may be warranted as chronic therapeutic 
inhibition of TLR7 and TLR9 signaling could potentially lead to increased susceptibility to 
infectious complications with microbial pathogens. While mice with mutations in specific 
TLRs or key TLR signaling molecules are more susceptible to infections, their clinical 
disease symptoms are often mild and occur primarily in experimental settings with high 
doses of pathogens. Furthermore, these mice are healthy in standard husbandry conditions, 
suggesting that other pathways can overcome these defects. This is true for influenza viral 
infection, which is controlled by at least three different classes of pattern recognition 
receptors, including TLR7, TLR8, the retinoic acid inducible gene-I (RIG-I) and Nod-like 
receptor family member, NLRP3. Influenza viral ssRNA recognition by TLR7 mediates 
signaling that leads to the production of antiviral cytokines, such as type I interferons, but 
TLR7 signaling is not required to mount an intact CD8+ T cell response. Instead NLPR3 and 
IL-1R signaling in DCs generates protective adaptive immunity by promoting CD8+ T cell 
responses to influenza virus. Lastly, increased susceptibility to viral infections has not been 
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noted in SLE patients prescribed hydroxychloroquine, a molecule that raises lysosomal pH 
and inhibits TLR signaling, or in SLE patients enrolled in clinical trials receiving TLR7 and 
TLR9 inhibitors. Thus, while mice deficient in TREML4 are more susceptible to influenza 
infection, more studies are needed to fully analyze the role of TREML4 in antiviral host 
defense to determine whether it may be possible to therapeutically inhibit TREML4-
mediated TLR7 signaling long-term for the treatment of autoimmune diseases without the 
potentially harmful complications that could arise from viral infections.
Methods
Reagents
Reagents were from Sigma-Aldrich unless otherwise stated. DMEM and RPMI-1640 were 
obtained from Invitrogen. Complete media consisted of RPMI-1640 or DMEM 
supplemented with 100U/ml penicillin, 100U/ml streptomycin, 2mM L-glutamine, and 10% 
fetal calf serum (FCS). Mouse TREM-like 4 antibody was purchased from BioLegend. All 
other antibodies were from eBioscience, unless otherwise specified. All TLR agonists were 
purchased from Invivogen. HEK293T cell line (Cat#: HCL4517) was obtained from Fisher 
Scientific and human THP-1 (Cat#: TIB-202) were obtained from ATCC. All cell lines were 
determined to be free of mycoplasma using a mycoplasma detection PCR Kit (Sigma). 
Influenza A/Puerto Rico/8/34 (PR8; ATCC, VR-1469) was grown in Madin Darby canine 
kidney cells in our laboratory.
Plasmids
Mouse Treml4 cDNAs were provided by H. Hemmi (Osaka University, Osaka, Japan) and 
R. Steinman (The Rockefeller University, New York, NY). Plasmids containing mouse TLR 
proteins were obtained from D. Golenbock (University of Massachusetts, Worcester, MA) 
or purchased from Invivogen.
Mice
All mice were maintained under micro-isolation in specific pathogen-free conditions at the 
Massachusetts General Hospital animal facility under a protocol approved by the 
Institutional Animal Care and Use Committee. Wild-type C57Bl/6 and SLE-prone MRL/lpr 
mice were purchased from The Jackson Laboratories. To generate TREML4-deficient mice, 
a targeting vector that contained 6239 bp of 5′ sequence upstream of the transcriptional start 
site, 4366 bp of 3′ sequence downstream of exon 4, and a neomycin resistance cassette 
replacing exons 2-4 was electroporated in C57Bl/6 ES cells. Targeted clones were selected 
in the presence of the antibiotic neomycin and identified by PCR and Southern blot analysis. 
Targeted ES clones were injected into C57BL/6 mice blastocysts by the Knockout Mouse 
Project (KOMP) at the University of California Davis, which resulted in several lines of 
chimeric mice that transmitted the disrupted allele through the germline DNA. The 
TREML4-deficient mice bred at normal mendelian ratios. Treml4–/– mice were backcrossed 
at least eight generations to Fas-deficient, SLE-prone MRL/lpr mice, at which point more 
than 99.8% of the genome was statistically derived from the MRL/lpr strain. These MRL/lpr 
Treml4–/– mice were then intercrossed to produce two cohorts of 16 MRL/lpr Treml4+/+ and 
16 MRL/lpr Treml4–/– mice (32 mice total each genotype), which were analyzed at 16 
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weeks of age. A third cohort of 47 MRL/lpr Treml4+/+ and 42 MRL/lpr Treml4–/– mice were 
observed without intervention until he time of death. Moribund animals were sacrificed and 
were included as deaths in the analysis. Genotyping primer pairs for discriminating between 
wild-type Treml4 and Treml4 knockout mice: WT Fw 5′-
CCCTTCCCAGTTCTGACTACC-3′; WT Rv 5′-
CAAACTCAGATACTCATGCTGGCTGC-3′; KO Fw 5′-
GATCAGGATGATCTGGACGAA-3′; KO Rv 5′- CATCATTGATCCAGCTCCCTA-3′. 
Wild-type Treml4 allele PCR is 449 bp and Treml4 mutant product is 1257 bp. Genotyping 
primer pairs for discriminating between wild-type Fas and lpr: WT Fw 5′-
AGCATAGATTCCATTTGCT-3′ and WT Rv 5′-AGTAATGGGCTCAGTGCA-3′; lpr Fw 
5′-AGCATAGATTCCATTTGCT-3′ and lpr Rv 5′-CAAATTTTATTGTTGCGACA-3′. 
PCR amplification conditions were: 94°C for 3 min; 30 cycles of 30 s each at 94°C, 58°C, 
and 72°C; followed by a 7 min incubation at 72°C.
Isolation of Bone Marrow-derived Dendritic Cells
For the enrichment of BMDCs, mice where euthanized and bone-marrow cells were 
harvested from the femurs and tibiae. Following treatment with RBC lysis buffer, the 
remaining cells were suspended at a final concentration of 1×106 cells/mL in RPMI-
complete media supplemented with 10% supernatant from J558L cells as a source of GM-
CSF. Cells were seeded in non-tissue culture treated Petri dishes and incubated at 37C with 
5% CO2, and cells were fed every 3 days. At day 8, cells were harvested and seeded 
according the experimental approach.
Purification of bone marrow-derived neutrophils
Marrow cavities of the femurs of 8-week old mice were flushed with DMEM. After 
hypotonic lysis of red blood cells, mature neutrophils were isolated by centrifugation for 30 
min at 28C and 500g over discontinuous Percoll gradients consisteing of 55%, 65% and 
75% (vol/vol) Percol in PBS. Mature neutrophils were recovered at the interface of the 65% 
and 75% fractions. Neutrophil purity was >90% as assessed by Ly6G and CD11b staining 
by flow cytometry.
Pooled shRNA screen
The genome-scale pooled shRNA assays were performed using 2.5 × 107 RAW-GFP 
reporter cells for each replicate placed in culture medium containing 4 μg/mL polybrene and 
the 45k pool shRNA lentivirus was added to achieve an MOI of 0.3. After 24 hours the 45k 
library infected cells were split into T175 flasks and selected in culture medium containing 
puromycin. Five days later, 1 × 108 infected cells were treated with GRD for 6 hours, 
harvested, stained with antibodies to detect intracellular TNF, and sorted into two 
populations by flow cytometry based on low and high dual TNF and NF-κB-GFP 
expression. The shRNA sequences were PCR amplified from the genomic DNA isolated 
from the sorted cells and hybridized to complementary microarrays to assess the abundance 
of each shRNA usinf Dchip software.
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Total RNA was extracted using the RNeasy kit and DNase treated according to the 
manufacturer's protocol (Qiagen), and each sample was reverse transcribed using multiscribe 
reverse transcriptase (Applied Biosystems). The 25-µl qPCR reaction contained 2 µl of 
cDNA, 12.5 µl of 2× SYBR green master mix (Applied Biosystems), and 500 nM of sense 
and antisense primers. Oligonucleotide primer sequences designed on the PrimerBank or 
Primer3 websites and obtained from Integrated DNA Technologies were as follows: human 
GAPDH, 5′-GAAGGTGAAGGTCGGAGTC-3′ and 5′- 
GAAGATGGTGATGGGATTTC-3′; human IL8, 5′-CTGGCCGTGGCTCTCTTG-3′ and 
5′-CCTTGGCAAAACTGCACCTT-3′; human TREML4, 5′-
GGGTGCTGTGCCTGAAGAA-3′ and 5′-AGGTACACCGACTTGGAGATG-3′; mouse 
TREML4, 5′-CCCTTCCCAGTTCTGACTACC-3′ and 5′-
GCACACAGAAAACTGACAGCA-3′; mouse GAPDH, 5′-
GGCAAATTCAACGGCACAGT-3′ and 5′-AGATGGTGATGGGCTTCCC-3′; mouse 
CXCL10, 5′- GCCGTCATTTTCTGCCTCA-3′ and 5′-CGTCCTTGCGAGAGGGATC-3′; 
mouse IL12β, 5′- TGGTTTGCCATCGTTTTGCTG-3′ and 5′-
ACAGGTGAGGTTCACTGTTTCT-3′; mouse CCL2, 5′-
TGGCTCAGCCAGATGCAGT-3′ and 5′-TTGGGATCATCTTGCTGGTG-3′; mouse 
CCL22, 5′-TACATCCGTCACCCTCTGCC-3′ and 5′-
CGGTTATCAAAACAACGCCAG-3′; mouse IL1α, 5′-
GCACCTTACACCTACCAGAGT-3′ and 5′-TGCAGGTCATTTAACCAAGTGG-3′; 
mouse TNF, 5′- CCCTCACACTCAGATCATCTTCT-3′ and 5′-
GCTACGACGTGGGCTACAG-3′; mouse Jun, 5′-CCTTCTACGACGATGCCCTC-3′ and 
5′-GGTTCAAGGTCATGCTCTGTTT-3′; mouse IL12α, 5′-
CGCAGAGTCTCGCCATTATGAT-3′ and 5′-TGGTTTGCCATCGTTTTGCTG-3′; mouse 
TLR7, 5′-ATGTGGACACGGAAGAGACAA-3′ and 5′-
GGTAAGGGTAAGATTGGTGGTG-3′; mouse IL1β, 5′-
ACCTGTCCTGTGTAATGAAAGACG-3′ and 5′-TGGGTATTGCTTGGGATCCA-3′; 
mouse IL18, 5′-GTGAACCCCAGACCAGACTG-3′ and 5′-
CCTGGAACACGTTTCTGAAAGA-3′; mouse CCR7, 5′-
TGTACGAGTCGGTGTGCTTC-3′ and 5′-GGTAGGTATCCGTCATGGTCTTG-3′; 
mouse ATF3, 5′-GAGGATTTTGCTAACCTGACACC-3′ and 5′-
TTGACGGTAACTGACTCCAGC-3′; mouse IRF7, 5′-
GAGACTGGCTATTGGGGGAG-3′ and 5′-GACCGAAATGCTTCCAGGG-3′; mouse 
TLR9, 5′-ATGGTTCTCCGTCGAAGGACT-3′ and 5′-GAGGCTTCAGCTCACAGGG-3′; 
mouse IRF8, 5′-CGGGGCTGATCTGGGAAAAT-3′ and 5′-
CACAGCGTAACCTCGTCTTC-3′; mouse CXCL9, 5′-
TCCTTTTGGGCATCATCTTCC-3′ and 5′-TTTGTAGTGGATCGTGCCTCG-3′; mouse 
STAT1, 5′-TCACAGTGGTTCGAGCTTCAG-3′ and 5′-
GCAAACGAGACATCATAGGCA-3′; mouse IFNβ, 5′-
CAGCTCCAAGAAAGGACGAAC-3′ and 5′-GGCAGTGTAACTCTTCTGCAT-3′; mouse 
IFNα4, 5′-TGATGAGCTACTACTGGTCAGC-3′ and 5′-
GATCTCTTAGCACAAGGATGGC-3′; mouse IL23α, 5′-
AATAATGTGCCCCGTATCCAGT-3′ and 5′-GCTCCCCTTTGAAGATGTCAG-3′; 
mouse MyD88, 5′-TCATGTTCTCCATACCCTTGGT and 5′-
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AAACTGCGAGTGGGGTCAG-3′; mouse IRAK1, 5′-CCACCCTGGGTTATGTGCC-3′ 
and 5′-GAGGATGTGAACGAGGTCAGC-3′; mouse IRAK4, 5′-
CATACGCAACCTTAATGTGGGG-3′ and 5′-GGAACTGATTGTATCTGTCGTCG-3′; 
mouse IRAK3, 5′-CTGGCTGGATGTTCGTCATATT-3′ and 5′-
GGAGAACCTCTAAAAGGTCGC-3′; mouse TRAF6, 5′-
AAAGCGAGAGATTCTTTCCCTG-3′ and 5′-ACTGGGGACAATTCACTAGAGC-3′; 
mouse TBK1, 5′-ACTGGTGATCTCTATGCTGTCA-3′ and 5′-
TTCTGGAAGTCCATACGCATTG-3′; mouse SYK, 5′-CTACCTGCTACGCCAGAGC-3′ 
and 5′-GCCATTAAGTTCCCTCTCGATG-3′; mouse DAP12, 5′-
GAGTGACACTTTCCCAAGATGC-3′ and 5′-CCTTGACCTCGGGAGACCA-3′; mouse 
IRF5, 5′-AGAGACAGGGAAGTACACTGAAG-3′ and 5′-
TGGAAGTCACGGCTTTTGTTAAG-3′; mouse STAT2, 5′-
CTGAAGGACGAACAGGATGTC-3′ and 5′-CAGGGTGGTTAATCGGCCAA-3′. 
Emitted fluorescence for each reaction was measured three times during the annealing-
extension phase, and amplification plots were analyzed with MX4000 software, version 3.0 
(Stratagene). The quantity of gene expression was generated by comparison of the 
fluorescence generated by each sample with standard curves of known quantities, and the 
calculated number of copies was divided by the number of copies of the housekeeping gene 
GAPDH.
Histological assessment
Histopathologic examination of kidney samples was done after routine fixation and paraffin 
embedding of the tissues. Tissue sections from the skin were cut and stained with Periodic 
acid-Shiff stain (PAS). All slides were coded and evaluated in a blinded manner with regard 
to identity of the sample. Pathologic changes in the kidney were graded according to the 
presence of glomerular, interstitial, perivascular inflammation and immune complex 
deposition. Scores ranging from 0 (normal) to 4 (most severely inflamed) were assigned for 
each of the 4 features. A minimum of 50 glomeruli were assessed to determine the 
glomerular index in each mouse. Sections were visualized using a Nikon Eclipse ME600 
fluorescent microscope equipped with a high resolution DXM1200C Nikon digital camera. 
Data were analyzed using NIS-Elements software (Nikon) and Adobe Photoshop.
Autoantibody profiles
ANA and Crithidia lucilae immunofluorescence assays (Bio-Rad) were performed 
according to the manufacturer's instructions, with serum at 1:160-1:5120 dilution and 1:80 
dilution for C. lucilae, and scored by an observer blinded to the genotype of the mice. For 
nucleosome and smRNP ELISAs, polystyrene plates were coated with either dsDNA and 
histones or smRNP complex antigens, respectively (Immunovision). After blocking with 1% 
BSA in PBS, serial dilutions of serum from 1:160 to 1:5120 were added. Specific antibodies 
were detected with HRP-conjugated goat anti-mouse IgG and absorbance at 405/630 nm 
was compared with monoclonal antibodies to quantitate.
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Lentivirus production and infection
Plasmids encoding lentiviruses expressing shRNA molecules were obtained from The RNAi 
Consortium shRNA Library. The shRNA target 21-mer sequences were: shControl, 
CCTAAGGTTAAGTCGCCCTCG; mouse shTREML4 #1, 
GCAGTGCCAATACAAGCCTAA; mouse shTREML4 #2, 
AGAAGTAACTGTTCTCAGAAA; mouse shMyD88, 
GCCAGCGAGCTAATTGAGAAA; human shTREML4 #1, 
TGACACAGAATGACTCGGGAT; human shTREML4 #2, 
ACGTCTCCTATGTGGACTCTT; human shTREML4 #3, 
GTGCCTGAAGAACTTCACAAA; human shTREML4 #4, 
GAATCTACAACGCTTCCGAAA; human shTREML4 #5, 
CCTCCATCAATGGCTCTGAGA. Plasmids were purified with a QIAprep Miniprep kit 
(Qiagen). Plasmids were then transfected into HEK293T cells along with pCMV-dR8.2 dvpr 
and pCMV-VSVG for the production of lentivirus. RAW-GFP or THP-1 cells were placed 
in 24-well tissue culture dishes (2 × 105 cells per well) and were infected with 100 μl 
unconcentrated shRNA lentiviral supernatant and polybrene (7.5 μg/ml). Cells were spun for 
30 min at 800g, media replaced, and incubated for 2 days. Infected cells were selected in 
complete RPMI medium containing 10% (vol/vol) FBS and puromycin (3 μg/ml) and were 
tested 1 week after infection. The shRNA knockdown efficiency was determined by qPCR.
Phospho-flow cytometry analysis
BMDCs were enriched as described above. BMDCs (2×106 cells/mL) were seeded in 5mL 
polypropelene tubes containing RPMI complete media. Cells were treated with 10 μg/mL of 
Gardiquimod (TLR7), 100 ng/mL LPS (TLR4) or 10U rIFNγ (Prepotech) for 25 minutes at 
37C with 5% CO2. Treated cells were fixed with cold 2% paraformaldehyde for 10 minutes 
at 4C. Cells were washed 3 times with cold FACS buffer (PBS supplemented with 2% FCS) 
and permeabilized with cold 100% methanol for 20 minutes on ice. Cells were washed twice 
to remove methanol and stained with fluorescently labeled antibodies CD11c-APC, p42/44-
Alexa488 (Y202/204; Cell Signaling), p38MAPK-PE (T180/Y182; Cell Signaling), 
pSTAT1 (S727; Cell Signaling clone D3B7), pSTAT1 (Y701; Cell Signaling clone 58D6). 
Secondary staining for pSTAT1 was performed using goat anti-Rabbit IgG fluorescently 
labeled with Alexa fluor 488 (Invitrogen). Samples were analyzed using Becton Dickinson 
FACSCalibur, data was collected using CellQuest Software and data were analyzed using 
FlowJo X version for Mac.
Western blots and Co-immunoprecipitation
Co-immunoprecipitation experiments were performed using BMDCs seeded in 6-well plates 
at a final concentration of 1×106 cells/mL in RPMI-complete media. Cells were incubated 
with 10 μg/mL Gardiquimod for 15 minutes at 37C with 5% CO2. Cells were harvested and 
lysed in 1× lysis buffer (Cell Signaling). Lysates were incubated with anti-mouse TLR7 
(Fisher Scientific) or anti-mouse IgG isotype control (Santa Cruz Biotech) for 24 h at 4C. 
Supernatants were incubated with Protein G agarose beads overnight at 4C. Precipitated 
proteins are eluted, separated by SDS-PAGE and immunoblotted with anti-mouse MyD88 
(Santa Cruz Biotech).
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BMDCs were seeded in confocal dishes (Mattek) at a final concentration of 1×105 cells/mL 
in RPMI-complete media. The following day, cells were treated with 10 μg/mL GRD for 5 
minutes and 15 minutes at 37C. Cells were carefully washed with PBS and fixed with 2% 
PFA for 10 minutes at room temperature in the dark. Fixed cells were permeabilized with 
SAP buffer (2% saponin in PBS) for 1 hour at 37C. Following permeabilization, BMDCs 
were intracellularly stained with antibodies to mouse TLR7, MyD88, EEA1, or LAMP1 
(Thermo Scientific), followed by staining with secondary antibodies fluorescently labeled 
with AlexaFluor488 or AlexFluor550 (Invitrogen). Cells were washed 3 times with PBS. 
Finally, DNA was stained with 1:1000 dilution of DAPI (Invitrogen) for 10 minutes at RT. 
Cells were visualized using a Nikon confocal microscope and analysis performed using ZEN 
software. Data analysis and processing of images was conducted using ImageJ software 
(NIH).
Phagocytosis assay
Latex beads (1 uM polystyrene, carboxylate modified, red fluorescent biotin labeled) were 
opsonized with 1 mg/mL anti-Biotin IgG and mouse serum for 1 hour at 37C. Next, they 
were washed twice with PBS. The opsonized latex beads were hen added to suspended 
neutrophils at a ratio of 25:1 and paced at 4C to determine binding or 37C to initiate 
phagocytosis. The samples were washed twice in PBS by centrifugation at 1500 rpm for 5 
minutes. After washing, the samples were fixed with 10% formalin and viewed with a Zeiss 
fluorescent microscope. The data are expressed as the percentage of cells that had 
internalized at least one latex bead (percent phagocytic) as well as by the number of 
internalized latex beads per 100 phagocytees × 100 (phagocytic index).
Transwell chemotaxis assasy
Chemotaxis was assayed in 96-well chemotaxis chambers with polycarbonate membranes 
(pore size, 5 uM; Neuroprobe). CyQUANT dye mix was used for quantification of migrating 
cells. After 2 h of incubation, fluorescence was measured in a FluoroSkan Ascent 
fluorescent plate reader. fMLP was placed in the bottom well of a Neuroprobe chemotaxis 
chamber. Cells were spun (100 μl, containing on average 4 × 104 cells), then were 
resuspended in 50 μl DMEM and placed on top of the filter in the chemotaxis chamber. 
After 3 h of incubation, the number of cells migrating to the lower chamber was determined 
with CyQUANT. The chemotactic index was determined by division of the number of 
migrating cells (as determined by CyQUANT fluorescence) by the number of input cells and 
the results were normalized to 1 on the basis of migration of untreated cells.
Infection with influenza
Mice were infected with a live PR8 influenza virus at 30-50 EID/gram in 50 µl PBS per 
mouse intranasally. Some mice were euthanized on day 10 after infection, and the lungs 
were harvested and the viral load determined by qPCR using the following primers: forward 
primer, 5′-CGGTCCAAATTCCTGCTGA-3′; and reverse primer, 5′-
CATTGGGTTCCTTCCATCCA-3-3′. Other mice were monitored for weight loss and 
survival daily for 14–18 days.
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Statistical calculations were performed using a statistical software package (GraphPad Prism 
5.0d). For comparisons of two groups, means ± SE were analyzed by the two-tailed unpaired 
Student t-test with the Bonferroni correction applied when making multiple comparisons. 
For comparisons of greater than two groups, significance was determining using the one- or 
two-way analysis of variance (ANOVA) with correction or Mann-Whitney Test. For 
survival studies, significance was determined using the log rank test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank B. Luo, M. Okamoto, and members of the Genetic Perturbation Platform (Broad Institute) and The RNAi 
Consortium (TRC) for shRNA lentiviral libraries and technical assistance. The vector, ES cell, and TREML4-
deficient mouse strain used for this research project was generated by the trans-NIH Knock-Out Mouse Project 
(KOMP) and obtained from the KOMP Repository (www.komp.org). NIH grants to Velocigene at Regeneron Inc 
(U01HG004085) and the CSD Consortium (U01HG004080) funded the generation of gene-targeted ES cells for 
8500 genes in the KOMP Program and archived and distributed by the KOMP Repository at UC Davis and CHORI 
(U42RR024244). Supported by the National Institutes of Allergy and Infectious Diseases (R01-AI084884 to 
T.K.M.; U24 AI082660 to J.E.K.; and T32-AI007061 to Z.G.R.-O.), the National Institutes of Arthritis, 
Musculoskeletal and Skin Diseases (K01-AR051367 to T.K.M.; K01-AR066716 to Z.G.R.-O), the National 
Institute of Diabetes and Digestive and Kidney Diseases (F32-DK097891 to W.F.P.), the Lupus Research Institute 
(T.K.M. and N.H.), the Alliance for Lupus Research (T.K.M. and N.H.) and the American Society of Nephrology 
(W.F.P.).
References
1. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate 
immunity. Nat Rev Immunol. 2013; 13:453–460. [PubMed: 23681101] 
2. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune 
system. Annu Rev Immunol. 2011; 29:185–214. [PubMed: 21219183] 
3. Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. Nature. 1991; 351:355–356. [PubMed: 
1851964] 
4. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4:499–511. [PubMed: 
15229469] 
5. Kono DH, Baccala R, Theofilopoulos AN. TLRs and interferons: a central paradigm in 
autoimmunity. Curr Opin Immunol. 2013; 25:720–727. [PubMed: 24246388] 
6. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a 
crucial mediator of septic shock. Nature. 2001; 410:1103–1107. [PubMed: 11323674] 
7. Turnbull IR, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006; 
177:3520–3524. [PubMed: 16951310] 
8. Hamerman JA, et al. Cutting edge: inhibition of TLR and FcR responses in macrophages by 
triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol. 2006; 177:2051–
2055. [PubMed: 16887962] 
9. Ornatowska M, et al. Functional genomics of silencing TREM-1 on TLR4 signaling in 
macrophages. Am J Physiol Lung Cell Mol Physiol. 2007; 293:L1377–1384. [PubMed: 17905855] 
10. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin 
Immunol. 2009; 21:38–46. [PubMed: 19230638] 
11. Washington AV, et al. TREM-like transcript-1 protects against inflammation-associated 
hemorrhage by facilitating platelet aggregation in mice and humans. J Clin Invest. 2009; 
119:1489–1501. [PubMed: 19436112] 
Ramirez-Ortiz et al. Page 18













12. Guerreiro R, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013; 368:117–127. 
[PubMed: 23150934] 
13. Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 
2013; 368:107–116. [PubMed: 23150908] 
14. Hamerman JA, Tchao NK, Lowell CA, Lanier LL. Enhanced Toll-like receptor responses in the 
absence of signaling adaptor DAP12. Nat Immunol. 2005; 6:579–586. [PubMed: 15895090] 
15. Hemmi H, et al. A new triggering receptor expressed on myeloid cells (Trem) family member, 
Trem-like 4, binds to dead cells and is a DNAX activation protein 12-linked marker for subsets of 
mouse macrophages and dendritic cells. J Immunol. 2009; 182:1278–1286. [PubMed: 19155473] 
16. N'Diaye EN, et al. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic 
receptor for bacteria. J Cell Biol. 2009; 184:215–223. [PubMed: 19171755] 
17. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production 
in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic 
or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004; 50:1861–1872. [PubMed: 15188363] 
18. Pisitkun P, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene 
duplication. Science. 2006; 312:1669–1672. [PubMed: 16709748] 
19. Subramanian S, et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. 
Proc Natl Acad Sci U S A. 2006; 103:9970–9975. [PubMed: 16777955] 
20. Deane JA, et al. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and 
dendritic cell proliferation. Immunity. 2007; 27:801–810. [PubMed: 17997333] 
21. Christensen SR, et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have 
opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006; 25:417–
428. [PubMed: 16973389] 
22. Berland R, et al. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody 
knockin mice. Immunity. 2006; 25:429–440. [PubMed: 16973388] 
23. Wang CM, et al. Genetic variations in Toll-like receptors (TLRs 3/7/8) are associated with 
systemic lupus erythematosus in a Taiwanese population. Sci Rep. 2014; 4:3792. [PubMed: 
24445780] 
24. Luo B, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U 
S A. 2008; 105:20380–20385. [PubMed: 19091943] 
25. Moffat J, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral 
high-content screen. Cell. 2006; 124:1283–1298. [PubMed: 16564017] 
26. Ramirez-Ortiz ZG, et al. The scavenger receptor SCARF1 mediates the clearance of apoptotic cells 
and prevents autoimmunity. Nat Immunol. 2013; 14:917–926. [PubMed: 23892722] 
27. Hemmi H, et al. Treml4, an Ig superfamily member, mediates presentation of several antigens to T 
cells in vivo, including protective immunity to HER2 protein. J Immunol. 2012; 188:1147–1155. 
[PubMed: 22210914] 
28. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of 
TLR7-mediated recognition of single-stranded RNA. Science. 2004; 303:1529–1531. [PubMed: 
14976261] 
29. Ramsauer K, et al. p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 
phosphorylation. Proc Natl Acad Sci U S A. 2002; 99:12859–12864. [PubMed: 12232043] 
30. Luu K, et al. STAT1 plays a role in TLR signal transduction and inflammatory responses. Immunol 
Cell Biol. 2014; 92:761–769. [PubMed: 25027037] 
31. Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol. 2009; 
10:340–347. [PubMed: 19295630] 
32. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat 
Immunol. 2006; 7:1266–1273. [PubMed: 17110943] 
33. Paradowska-Gorycka A, Jurkowska M. Structure, expression pattern and biological activity of 
molecular complex TREM-2/DAP12. Hum Immunol. 2013; 74:730–737. [PubMed: 23459077] 
34. Paloneva J, et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia 
with bone cysts. Nat Genet. 2000; 25:357–361. [PubMed: 10888890] 
Ramirez-Ortiz et al. Page 19













35. Paloneva J, et al. Mutations in two genes encoding different subunits of a receptor signaling 
complex result in an identical disease phenotype. Am J Hum Genet. 2002; 71:656–662. [PubMed: 
12080485] 
36. Gibot S, et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the 
inflammatory response in murine sepsis. J Exp Med. 2004; 200:1419–1426. [PubMed: 15557347] 
37. Piccio L, et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with 
multiple sclerosis and CNS inflammation. Brain. 2008; 131:3081–3091. [PubMed: 18790823] 
38. Kleinberger G, et al. TREM2 mutations implicated in neurodegeneration impair cell surface 
transport and phagocytosis. Sci Transl Med. 2014; 6:243ra286.
39. Sen SK, et al. Integrative DNA, RNA, and protein evidence connects TREML4 to coronary artery 
calcification. Am J Hum Genet. 2014; 95:66–76. [PubMed: 24975946] 
40. Silbiger VN, et al. Novel genes detected by transcriptional profiling from whole-blood cells in 
patients with early onset of acute coronary syndrome. Clin Chim Acta. 2013; 421:184–190. 
[PubMed: 23535507] 
41. Christensen SR, et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine 
lupus. J Exp Med. 2005; 202:321–331. [PubMed: 16027240] 
42. Herlands RA, Christensen SR, Sweet RA, Hershberg U, Shlomchik MJ. T cell-independent and 
toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity. 2008; 
29:249–260. [PubMed: 18691914] 
43. Nickerson KM, et al. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and 
disease in a murine model of lupus. J Immunol. 2010; 184:1840–1848. [PubMed: 20089701] 
44. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a 
dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration 
of disease symptoms. Eur J Immunol. 2007; 37:3582–3586. [PubMed: 18034431] 
45. Thibault DL, et al. IRF9 and STAT1 are required for IgG autoantibody production and B cell 
expression of TLR7 in mice. J Clin Invest. 2008; 118:1417–1426. [PubMed: 18340381] 
Ramirez-Ortiz et al. Page 20














TREML4 positively regulates TLR7 signaling.
(a) Expression analysis of shRNAs present in the TNFloGFPlo sorted population of RAW-
GFP macrophages treated with GRD for 6 h compared to the TNFhiGFPhi subset. Data 
within the green border represent 257 enriched shRNAs with a log fold change (LFC) >2; 
P<0.05. (b) Quantitative PCR analysis of Treml4 mRNA in RAW-GFP cells transduced 
with viruses containing shRNAs targeting Treml4 (shTREML4) or scrambled control 
(shCtrl). (c) Immunoblot analysis of TREML4 and GAPDH (loading control) in RAW-GFP 
transduced with shRNA lentiviruses targeting TREML4. (d) Flow cytometry analysis of 
TNF and GFP in RAW-GFP transduced with shTREML4 treated with 10 μg/mL of GRD for 
6 h. (e) Flow cytometry analysis of TNF and GFP in RAW-GFP transduced with shRNA 
lentiviruses targeting MyD88 or TREML4 treated with specified TLR agonists for 4 h. Data 
presented as the percentage induction relative to shCtrl. (f) Quantitative PCR analysis of Il8 
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mRNA in HEK expressing TREML4 and/or TLR7 treated with GRD for 3 h. (g) 
Quantitative PCR analysis of Il8 mRNA in HEK transfected with TLR7 and/or 
TREML4(WT), TREML4(K210L), or TREML4(Δcyto) treated with 10 μg/mL GRD for 3 h. 
(h) Quantitative PCR analysis of Il8 mRNA in THP-1 transduced with lentivirus encoding 
shRNAs targeting unique sequences in the human Treml4 gene treated with 10 μg/mL GRD 
for 3 h. *P<0.05 and **P<0.01 (Mann-Whitney test). Data are representative of an 
experiment done three times (b,d-g; median and s.d. of at least triplicates).
Ramirez-Ortiz et al. Page 22














Regulation of TLR7 signaling by TREML4.
(a) Quantitative PCR analysis of Treml4 mRNA in F4/80+ splenic macrophages isolated 
from Treml4+/+ mice treated with 10 μg/mL GRD or CpG-DNA for 1, 3, or 8 h. (b) 
Quantitative PCR analysis of Treml4 mRNA in the blood of Treml4+/+, Treml4+/– and 
Treml4–/– mice. (a,b) Data presented as copies of Treml4 mRNA normalized to copies of 
Gapdh mRNA. (c) Immunoblot analysis of TREML4 and GAPDH (loading control) in 
spleen extracts isolated from Treml4+/+, Treml4+/– and Treml4–/– mice. (d) Quantitative 
PCR analysis of the indicated inflammatory genes in F4/80+ splenic macrophages isolated 
from Treml4–/– and wild-type mice treated with 10 μg/mL GRD for 4 h. (e) Quantitative 
PCR analysis of Tnf mRNA in F4/80+ splenic macrophages isolated from Treml4+/+ and 
Treml4–/– mice treated with the specified TLR ligand for 4 h. (d,e) Data presented as fold 
mRNA over untreated. (f) ELISA of TNF, IL12p40, IFN-β and CXCL10 in supernatants of 
Ramirez-Ortiz et al. Page 23













F4/80+ splenic macrophages isolated from Treml4+/+ and Treml4–/– mice treated with CpG-
DNA (10 μg/mL), GRD (10 μg/mL) or LPS (100 ng/mL) for 18 h. (ND, none detected). 
*P<0.01 (Mann-Whitney test). Data are from one experiment representative of at least three 
independent experiments performed (b,d-f; error bars, median and s.d. of triplicates).
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In vivo regulation of TLR7 signaling by TREML4.
(a) Quantitative PCR analysis of Tnf, Il12b, Ifnb and Cxcl10 mRNA in splenic cells from 
Treml4+/+ and Treml4–/– mice (n=9) injected intravenously with 100 μg/mL GRD, 100 
μg/mL R-848, 100 μg/mL CpG-DNA, or 10 μg/mL LPS, or intranasally with 5 × 106 PFU 
live influenza virus for 8h. Data presented as fold over saline injected mice. (b) Flow 
cytometry analysis of intracellular TNF expression in F4/80+CD11b+CD11c– splenic 
macrophages isolated from Treml4+/+ and Treml4–/– mice injected and treated as in (a). (c) 
ELISA of TNF, IL12p40, IFN-β and CXCL10 in the sera of mice injected and treated as in 
(a,b). (d) Weight loss analysis of Treml4+/+ and Treml4–/– mice (n=10) injected intranasally 
with sublethal dose of influenza PR8 virus (34 EID/gram). (e) Quantitative PCR analysis of 
influenza PR8 mRNA in the lungs of mice at day 10 after influenza infection. (f) Survival of 
Treml4+/+ and Treml4–/– mice (n=12) following infection with LD25 influenza PR8 (50 
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EID/gram). *P<0.01 (Mann-Whitney test). Data are from one experiment representative of 
at least three independent experiments performed (a,c,e; error bars, mean and s.d. of 
triplicates). **P<0.0001 (two-way ANOVA). ***P<0.01 (log rank test).
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TLR7-induced phosphorylation of MAPKs and STAT1 is regulated by TREML4.
(a-d) Phosphoflow cytometry analysis of p44p42 (a), p38 (b), pSTAT1(S727) (c) and 
pSTAT1(Y701) (d) in CD11c+ BMDCs isolated from Treml4+/+ and Treml4–/– mice treated 
with 100 ng/mL LPS, 10 μg/mL GRD, or 10 μg/mL CpG-DNA for 30 min. Histograms are 
representative of one experiment of 3 independent experiments performed. Graphs represent 
the mean fluorescent intensity (MFI). *P<0.01 (Student's t-test; error bars, mean and s.d.).
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TREML4 regulates MyD88 and TLR7 trafficking and localization.
(a) Immunoblot analysis of TLR7 and MyD88 of TLR7 immunoprecipitates from BMDC 
generated from Treml4–/– and wild-type mice stimulated with GRD for 15 min. (b, c) 
Double immunofluorescence of TLR7 and MyD88, EEA1, or LAMP1 on BMDC generated 
from Treml4–/– and wild-type mice stimulated for 5 or 15 min. Data show a representative 
experiment of at least 3 independent experiments performed. *P<0.01 (b-c; Student's t-test; 
error bars, mean and s.d.).
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Ameliorated autoimmunity in TREML4-deficient MRL/lpr mice.
(a) ANA immunofluorescence staining pattern of HEp-2 cells with sera from 16-week old 
MRL/lpr Treml4–/– and MRL/lpr mice. Shown is the percentage of mice positive for nuclear 
homogenous (Hom), nuclear speckled (Speck), or cytoplasmic (Cyt) staining pattern. (b-d) 
ELISA of anti-nucleosome (dsDNA/histone) (b), anti-dsDNA (c) and anti-Sm-RNP 
antibodies (d) in the serum of 16 week old MRL/lpr Treml4–/– and MRL/lpr mice (n=16 
mice per group). (e,f) Flow cytometry analysis of immune cell distribution (e) and 
percentage of CD44+CD4+ activated T cells (f) in the spleen of MRL/lpr Treml4–/– and 
MRL/lpr mice at 16 weeks of age (n=8 mice per group). (g) Quantitative PCR analysis of 
cytokine mRNA in spleen of MRL/lpr Treml4–/– and MRL/lpr mice at 16 weeks of age (n=8 
mice per group). (h) ELISA of IFN-α in the sera of 16 week old MRL/lpr Treml4–/– and 
MRL/lpr mice (n=16 mice per group). (i) Histopathologic analysis of PAS stained kidney 
cryosections isolated from 16 week-old MRL/lpr Treml4–/– and MRL/lpr. (j) Composite 
renal disease score based glomerular inflammation, glomerular IgG deposition, urine 
proteinuria, and blood urea nitrogen concentration (n=16 mice per group). Each parameter 
Ramirez-Ortiz et al. Page 29













scored 1 to 4 for each animal, higher number indicates increased disease severity. (k) 
Survival of MRL/lpr (n=47) and MRL/lpr Treml4–/– (n=42) mice. *P<0.01 (e, f, j, Student's 
t-test; a-d, g-h, Mann-Whitney test) and **P<0.0001 (k, log rank test).
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